摘要
抗体工程药物是生物制药技术领域的重要组成部分之一。随着杂交瘤细胞、基因工程和分子免疫学、抗体库等技术不断建立和完善以及发展和应用,为单克隆抗体药物的制备和规模化、规范化生产奠定了良好的基础,也使抗体药物的研制与应用达到了新的高度。特别是,单克隆抗体药物的特异性高、均质性好、亲和力强、靶向性佳、毒副作用小、疗效确切等特点使其成为当今基因工程药物研究的热点。而老年病因其复杂性、多样性、多系统器质性病变及难治性等特点,在有效的临床药物治疗方面一直是同学科领域关注的焦点和重点。为此,本文将对某些单克隆抗体目前在老年病中的临床研究和应用情况进行综述,并对其未来应用前景和发展方向及其趋势进行展望,期待有些抗体药物能在老年病的临床诊断和治疗上得以广泛应用,也为临床相关老年性疾病的诊断和治疗带来新的希望。
Antibody engineering pharmaceutics is an indispensible part of biological pharmaceutical technology. Based on the establishment, improvement, development and applications of hybridoma, genetic engineering, molecular immunology and antibody li- brary, the massive and standardizing preparation and manufacturing of monoclonal antibody have been possible and also elevate the manufacturing and application of antibody pharmaceutics. Especially monoclonal antibody medicine is characterized by high specificity, homogeneity, affinity and targeting, low toxic and side- effect, and ensured effectiveness, which makes it the focus of genetic engi- neering pharmaceutics. The effectiveness of clinical treatment of the senile diseases has also been the focus of researches because of their characteristics of complexity, variety, multisystemic organic diseases and intractability. The article reviews the applications of some monoclonal antibodies in clinical treatment and foresees the future development and the prospect of their applications in order to hope a broad application of some antibody based drugs in the clinical diagnosis and treatment of senile diseases. It is hoped that the article will bring a new hope to the clinical diagnosis and treatment of the related senile diseases.
出处
《国际老年医学杂志》
2010年第5期196-202,共7页
International Journal of Geriatrics
关键词
单克隆抗体
抗体工程药物
老年病
临床治疗
研究进展
Monoclonal antibody
Antibody engineering pharmacentics
Senile diseases
Clinical treatment
Theoretical development
